RecruitingEarly Phase 1NCT06150365

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

12 participants

Start Date

Nov 7, 2023

Study Type

INTERVENTIONAL

Conditions

Refractory Solid Tumors Relapsed Solid Tumors

Summary

This trial is a single arm, open phase I clinical study to investigate the safety and efficacy of personalized KSX01-TCRT in patients with advanced solid tumors. This experiment is divided into two parts: the dose increasing stage (Part A) and the dose expanding stage (Part B). For those enrolled in the planned expansion phase, the dose should have passed the safety assessment during the dose escalation phase.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called KSX01-TCRT cell therapy for people with refractory solid tumors and relapsed solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.